Forward P/S Multiple: Surmodics (SRDX)

Surmodics, Inc. - graphic logo of issuer SRDX

Surmodics, Inc. (SRDX) controls the synthesis of reagents, outsourcing only external catheter testing to contractors. After evaluating the forward P/S multiple on GURU.Markets, we find that 5.10 reflects the current metric volume, linking price to future sales. This complements the company's status as a key supplier of hydrophilic coatings for stents. Growth in shipments coupled with high margins creates operating leverage, reducing R&D costs.

surmodics.com - SRDX Market Cap to Projected Revenue (period 07/04/2022 - 11/29/2025)

Summary analytical data breakdowns for Surmodics Inc. (SRDX)

- market price and analyst price targets:
Price Chart Surmodics|SRDX - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization Surmodics Inc.|SRDX - Total Enterprise Value
- issuer book value statistics:
Book Value per Share Surmodics|SRDX - Accounting Capitalization|Market Capitalization to Book Value Ratio surmodics.com|SRDX - Company Total Asset Base
- debt and liquidity data:
Total Debt to Capital Surmodics, Inc.|SRDX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Surmodics, Inc.|SRDX - Company Aggregate Debts|Debt to Book Capitalization Ratio Surmodics Inc.|SRDX - Company Long-Term Debt|Company Current Liabilities Surmodics|Quick Ratio surmodics.com
- financial results and valuation multiples details:
SRDX - Company Net Income|Expected Profit Surmodics, Inc.|SRDX - Market Cap to Net Income Ratio|Projected Price to Earnings Surmodics Corp|SRDX - PEG Multiple|EV/EBITDA Multiple Surmodics Inc.|SRDX - Operating income before deduction of amortization|Earnings per share for the last twelve months Surmodics|SRDX - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months surmodics.com|SRDX - Net earnings per share growth this year|Earnings growth forecast for next year Surmodics, Inc.
- sales and revenue indicators:
SRDX - Company Total Revenue|Company Projected Revenue Surmodics|SRDX - Market Cap to Revenue Ratio|Forward Price-to-Revenue Multiple Surmodics Inc.
Fundamental company analysis:SRDX (Surmodics)
Product sample of Surmodics Inc.

Forward P/S is calculated as the ratio of the current market value of the business to projected annual revenue, reflecting the premium the market is willing to pay for future sales. The future P/S dynamics of the issuer allow for an assessment of how effectively the capitalization of Surmodics, Inc. (SRDX) prices in the stability of supplies from high-tech plants in the US and Ireland amid strict production sterility requirements.

Who Surmodics, Inc. competes with

Price-to-Projected Revenue Ratio Dexcom DXCM|PEN - Forward Price-to-Revenue Multiple|Novanta Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Haemonetics Company|INSP: Forward P/S Multiple|Market Cap to Projected Revenue PRCT|CNMD (CONMED) - Forward P/S Multiple|Pulse Biosciences Inc (PLSE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple INMD|Forward Price-to-Revenue Multiple Picard Group PMI|Forward P/S Multiple SENS (Senseonics Holdings)|Forward P/S Multiple neuropace.com NPCE|TCMD - Price-to-Projected Revenue Ratio|SNWV: Price-to-Projected Revenue Ratio|OM (Outset) - Forward Price-to-Revenue Multiple|Electromed - Forward Price to Sales|LNSR (LENSAR, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio avitamedical.com RCEL|Price-to-Projected Revenue Ratio Profound Medical Corp. (PROF)|bairdmed.com (BDMD) - Projected Price to Revenue|EDAP TMS - Forward Price-to-Revenue Multiple|Forward P/S Multiple Apyx Medical Corp APYX|IceCure Medical, Ltd. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Pulmonx Corporation LUNG|telabio.com (TELA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CTSO (CytoSorbents Corporation)|Price-to-Projected Revenue Ratio Sensus Healthcare Corp|Forward Price-to-Revenue Multiple Zynex Corp (ZYXI)|Forward P/S Multiple ECOR|RBOT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Inspira Technologies IINN|ICU: Market Cap to Projected Revenue|IRIX: Forward Price-to-Revenue Multiple|Intelligent Bio Solutions - Price to Expected Revenue Ratio|beyondair.net (XAIR) - Price-to-Projected Revenue Ratio|PFSA - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple SSKN|Forward P/S Multiple glucotrack.com|Price-to-Projected Revenue Ratio NanoVibronix (NAOV)|VERO (Venus Concept Corporation) - Forward Price to Sales|Price-to-Projected Revenue Ratio Nuwellis, Inc. NUWE|AEMD - Forward Price-to-Revenue Multiple|ASXC - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Avinger Inc.|BSGM: Forward P/S Multiple|Market Cap to Projected Revenue CUTR|KNW (Know Labs, Inc.) - Forward P/S Multiple|inarimedical.com (NARI) - Market Cap to Expected Sales Ratio|Forward P/S Multiple NVRO|Forward Price-to-Revenue Multiple reshapelifesciences.com RSLS|Price-to-Projected Revenue Ratio Silk Road Medical Inc. SILK